p53 in esophageal adenocarcinoma: A critical reassessment of mutation frequency and identification of 72Arg as the dominant allele

International Journal of Oncology

Volumn 31, Issue 6, 2007, Pages 1351-1355

  Chung, Sun M ^a   Kao, Jean ^a   Hyjek, Elizabeth ^a   Chen, Yao Tseng ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Barrett's esophagus; Laser microdissection; p53

Indexed keywords

PROTEIN P53;

ADENOCARCINOMA; ALLELE; ARTICLE; ESOPHAGUS TUMOR; EXON; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MUTATION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ALLELES; ESOPHAGEAL NEOPLASMS; EXONS; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38449118437     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.6.1351     Document Type: Article

References (34)

1. Lane DP: Cancer. p53, guardian of the genome. Nature 358: 15-16, 1992.
2. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
3. Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levin B and Roth JA: p53 gene mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51: 4495-4499, 1991.
4. Neshat K, Sanchez CA, Galipeau PC, et al: p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. Gastroenterology 106: 1589-1595, 1994.
5. Hamelin R, Flejou JF, Muzeau F, et al: TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 107: 1012-1018, 1994.
6. Gleeson CM, Sloan JM, McGuigan JA, Ritchie AJ and Russell SE: Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. Cancer Res 55: 3406-3411, 1995.
7. Schneider PM, Casson AG, Levin B, et al: Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. J Thorac Cardiovasc Surg 111: 323-331, 1996.
8. Gonzalez MV, Artimez ML, Rodrigo L, et al: Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. J Clin Pathol 50: 212-217, 1997.
9. Gleeson CM, Sloan JM, McManus DT, et al: Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. Br J Cancer 77: 277-286, 1998.
10. Schneider PM, Stoeltzing O, Roth JA, et al: P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Clin Cancer Res 6: 3153-3158, 2000.
11. Ireland AP, Shibata DK, Chandrasoma P, Lord RV, Peters JH and DeMeester TR: Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia. Ann Surg 231: 179-187, 2000.
12. Bian YS, Osterheld MC, Bosman FT, Benhattar J and Fontolliet C: p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod Pathol 14: 397-403, 2001.
13. Taniere P, Martel-Planche G, Maurici D, et al: Molecular and clinical differences between adenocarcinomas of the esophagus and of the gastric cardia. Am J Pathol 158: 33-40, 2001.
14. Doak SH, Jenkins GJ, Parry EM, et al: Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma. Br J Cancer 89: 1729-1735, 2003.
15. Dolan K, Walker SJ, Gosney J, Field JK and Sutton R: TP53 mutations in malignant and premalignant Barrett's esophagus. Dis Esophagus 16: 83-89, 2003.
16. Djalilvand A, Pal R, Goldman H, Antonioli D and Kocher O: Evaluation of p53 mutations in premalignant esophageal lesions and esophageal adenocarcinoma using laser capture microdissection. Mod Pathol 17: 1323-1327, 2004.
17. Gimenez A, Minguela A, Parrilla P, et al: Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Cancer 83: 641-651, 1998.
18. Feith M, Stein HJ, Mueller J and Siewert JR: Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53. Dis Esophagus 17: 322-327, 2004.
19. Younes M, Lebovitz RM, Lechago LV and Lechago J: p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. Gastroenterology 105: 1637-1642, 1993.
20. Rice TW, Goldblum JR, Falk GW, Tubbs RR, Kirby TJ and Casey G: p53 immunoreactivity in Barrett's metaplasia, dysplasia, and carcinoma. J Thorac Cardiovasc Surg 108: 1132-1137, 1994.
21. Vähäkangas KH, Castren K and Welsh JA: Single-strand conformation polymporphism analysis of mutations in exons 4-8 of the TP53 gene. In: Methods in Molecular Medicine. Killeen AA (ed). Vol. 49. Humana Press, Totowa, pp15-27, 2001.
22. Rideout WM, Coetzee GA, Olumi AF and Jones PA: 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249: 1288-1290, 1990.
23. Renault B, van den Broek M, Fodde R, et al: Base transitions are the most frequent genetic changes at P53 in gastric cancer. Cancer Res 53: 2614-2617, 1993.
24. Hollstein MC, Metcalf RA, Welsh JA, Montesano R and Harris CC: Frequent mutation of the p53 gene in human esophageal cancer. Proc Natl Acad Sci USA 87: 9958-9961, 1990.
25. Wagata T, Shibagaki I, Imamura M, et al: Loss of 17p, mutation of the p53 gene, and overexpression of p53 protein in esophageal squamous cell carcinomas. Cancer Res 53: 846-850, 1993.
26. Beckman G, Birgander R, Sjalander A, et al: Is p53 polymorphism maintained by natural selection? Hum Hered 44: 266-270, 1994.
27. Dumont P, Leu JI, Della Pietra AC, George DL and Murphy M: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33: 357-365, 2003.
28. Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108: 196-199, 2004.
29. Fan R, Wu MT, Miller D, et al: The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9: 1037-1042, 2000.
30. Tsai MH, Lin CD, Hsieh YY, et al: Prognostic significance of the proline form of p53 codon 72 polymorphism in nasopharyngeal carcinoma. Laryngoscope 112: 116-119, 2002.
31. Jones JS, Chi X, Gu X, Lynch PM, Amos CI and Frazier ML: p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 10: 5845-5849, 2004. (Pubitemid 39180964)
32. Soulitzis N, Sourvinos G, Dokianakis DN and Spandidos DA: p53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 179: 175-183, 2002.
33. Zhang ZW, Newcomb P, Hollowood A, et al: Age-associated increase of codon 72 Arginine p53 frequency in gastric cardia and non-cardia adenocarcinoma. Clin Cancer Res 9: 2151-2156, 2003.
34. Sullivan A, Syed N, Gasco M, et al: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 23: 3328-3337, 2004.